New analysis presented by the company, together with an improved discount to the price of vamorolone, mean that NICE can now ...

Suggested remit: To appraise the clinical and cost effectiveness of glycopyrronium bromide cream within its marketing authorisation for treating severe primary axillary hyperhidrosis.

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Around a quarter of a million people living with obesity will be offered the weight loss drug tirzepatide, alongside a reduced-calorie diet and increased physical activity, over the next three years, ...

Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

There is a simple discount patient access scheme for bevacizumab gamma. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by the chair and vice chair of NICE's highly specialised technologies evaluation committee.